ORA
Flash Placeholder
Medical ProfessionalsStudy Participants

Accelerating Drug Development
and Improving Patient Care.

Ora is the world’s leading independent ophthalmic drug and device development firm, with more than 30 NDA approvals during its 30-year history.

Ora provides technology-based, concept-to-market services and solutions that accelerate development timelines and improve the scientific quality of clinical research.

By doing so, we are able to help bring important drugs and devices to market faster, and improve patient care around the world.

 

Recent News

Eyegate Pharma Annouces that EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study

2009 06 03 Waltham, MA Based on the top level analysis of a Phase II study, EyeGate Pharma announces that EGP 437, a corticosteroid solution administered by a non invasive ocular drug delivery system, improved signs and symptoms in

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

PARIS,France/PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis.